TNSN99024A1 - Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque - Google Patents

Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque

Info

Publication number
TNSN99024A1
TNSN99024A1 TNTNSN99024A TNSN99024A TNSN99024A1 TN SN99024 A1 TNSN99024 A1 TN SN99024A1 TN TNSN99024 A TNTNSN99024 A TN TNSN99024A TN SN99024 A TNSN99024 A TN SN99024A TN SN99024 A1 TNSN99024 A1 TN SN99024A1
Authority
TN
Tunisia
Prior art keywords
treatment
heart failure
pharmaceutical composition
preparation
phenoxy
Prior art date
Application number
TNTNSN99024A
Other languages
English (en)
Inventor
Liang Chen Yuhpyng
Andrea Fossa Anthony
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN99024A1 publication Critical patent/TNSN99024A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE UN PROCEDE DE TRAITEMENT D'UN MAMMIFERE ATTEINT D'INSUFFISANCE CARDIAQUE, COMPRENANT L'ADMINISTRATION A CE MAMMIFERE D'UNE QUANTITE THERAPEUTIQUEMENT EFFICACE DE 4 - (1 - ETHYL - PROPOXY)-3,6 - DIMETHYL - 2 - (2,4,6 - TRIMETHYL - PHENOXY) - PYRIDINE ET DE (3,6 - DIMETHYL - 2 -(2,4,6 - TRIMETHYL - PHENOXY) - PYRIDINE - 4 - YL) - (1-ETHYL - PROPYL)- AMINE OU D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CE COMPOSE. ELLE CONCERNE AUSSI L'UTILISATION EN ASSOCIATION DE CES DEUX AGENTS AVEC D'AUTRES COMPOSES DE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE CONGESTIVE POUR TRAITER CE TYPE D'INSUFFISANCE CARDIAQUE. ELLE CONCERNE AUSSI UNE COMPOSITION PHARMACEUTIQUE CONTENANT CE OU CES COMPOSES INDIVIDUELLEMENT OU EN ASSOCIATION, AINSI QU'UN KIT UTILISE DANS LE PROCEDE DE TRAITEMENT, COMPRENANT UNE QUANTITE DU OU DES COMPOSES ACTIFS, UNE QUANTITE D'AGENTS DE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE CONGESTIVE ET UN RECIPIENT.
TNTNSN99024A 1998-02-17 1999-02-16 Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque TNSN99024A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7493498P 1998-02-17 1998-02-17

Publications (1)

Publication Number Publication Date
TNSN99024A1 true TNSN99024A1 (fr) 2005-11-10

Family

ID=22122537

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99024A TNSN99024A1 (fr) 1998-02-17 1999-02-16 Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque

Country Status (28)

Country Link
US (1) US6043260A (fr)
EP (1) EP0951906A1 (fr)
JP (1) JPH11292766A (fr)
KR (1) KR19990072616A (fr)
CN (1) CN1231176A (fr)
AP (1) AP9901464A0 (fr)
AR (1) AR017723A1 (fr)
AU (1) AU1732999A (fr)
BG (1) BG103180A (fr)
BR (1) BR9900653A (fr)
CA (1) CA2262252C (fr)
EA (1) EA199900124A3 (fr)
GT (1) GT199900015A (fr)
HR (1) HRP990054A2 (fr)
HU (1) HUP9900386A3 (fr)
ID (1) ID23218A (fr)
IL (1) IL128531A0 (fr)
IS (1) IS4975A (fr)
MA (1) MA26608A1 (fr)
NO (1) NO990722L (fr)
OA (1) OA10976A (fr)
PA (1) PA8467401A1 (fr)
PE (1) PE20000266A1 (fr)
PL (1) PL331507A1 (fr)
SG (1) SG81261A1 (fr)
TN (1) TNSN99024A1 (fr)
TR (1) TR199900328A2 (fr)
ZA (1) ZA991220B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US6387894B1 (en) * 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
AU3885901A (en) * 1999-09-21 2001-04-24 Emory University Methods and compositions for treating platelet-related disorders
EE200200400A (et) * 2000-01-18 2003-10-15 Pfizer Products Inc. Kortikotropiini vabastava faktori antagonistid
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
EP1476165A1 (fr) 2002-02-22 2004-11-17 PHARMACIA & UPJOHN COMPANY Pyrimidinones et pyrimidinthiones substitues
CA2478715A1 (fr) * 2002-03-13 2003-09-25 Pharmacia & Upjohn Company Nouveaux derives de pyrazolo(1,5-a)pyridine utilises en tant que modulateurs du neurotransmetteur
CA2480497A1 (fr) * 2002-04-26 2003-11-06 Pharmacia & Upjohn Company Derives pyraziniques substitues
AU2003269949A1 (en) * 2002-09-12 2004-04-30 Pharmacia & Upjohn Company Llc Substituted 1,4-pyrazine derivatives
AR041470A1 (es) * 2002-10-17 2005-05-18 Upjohn Co Compuestos de pirrolo (1,2 - b) piridazina y sus usos
EP1565454A1 (fr) * 2002-11-21 2005-08-24 Pharmacia & Upjohn Company LLC Composes de pyrazine en tant que modulateurs de crf
BRPI0409649A (pt) * 2003-04-23 2006-04-25 Pharmacia & Upjohn Co Llc pirimidinonas e pirimidinotionas substituìdas como antagonistas de crf
CA2523072A1 (fr) * 2003-05-07 2004-11-18 Pharmacia & Upjohn Company Llc Composes pyrrolo[1,2-b]pyridaziniques
MXPA05012082A (es) * 2003-05-09 2006-02-22 Pharmacia & Upjohn Co Llc Compuestos como antagonistas del receptor crf1.
JP2006525989A (ja) * 2003-05-09 2006-11-16 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Ｃｎｓ障害を治療するためのｃｒｆ１受容体アンタゴニストとしてのピラジノン
MXPA05012081A (es) * 2003-05-09 2006-02-22 Pharmacia & Upjohn Co Llc Derivados de pirimidina sustituidos.
WO2005089639A2 (fr) * 2004-03-16 2005-09-29 Talarico M D Matthew T Procede de deregulation vasculaire
US20060211710A1 (en) * 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
EP0795327A1 (fr) * 1996-03-13 1997-09-17 Pfizer Inc. Utilisation de l'amlodipine pour le traitement et la prophylaxie de l'insuffisance cardiaque congestive d'origine non-ischémique

Also Published As

Publication number Publication date
ZA991220B (en) 2000-08-16
IL128531A0 (en) 2000-01-31
AU1732999A (en) 1999-09-02
PL331507A1 (en) 1999-08-30
KR19990072616A (ko) 1999-09-27
BG103180A (bg) 1999-09-30
NO990722L (no) 1999-08-18
HUP9900386A3 (en) 1999-12-28
US6043260A (en) 2000-03-28
HRP990054A2 (en) 2000-02-29
HUP9900386A2 (hu) 1999-11-29
CA2262252A1 (fr) 1999-08-17
IS4975A (is) 1999-08-18
TR199900328A2 (xx) 1999-10-21
CN1231176A (zh) 1999-10-13
PA8467401A1 (es) 2000-09-29
EP0951906A1 (fr) 1999-10-27
SG81261A1 (en) 2001-06-19
CA2262252C (fr) 2006-01-10
OA10976A (en) 2001-11-05
JPH11292766A (ja) 1999-10-26
ID23218A (id) 2000-03-30
MA26608A1 (fr) 2004-12-20
NO990722D0 (no) 1999-02-16
AP9901464A0 (en) 1999-03-31
HU9900386D0 (en) 1999-04-28
BR9900653A (pt) 2000-10-17
EA199900124A2 (ru) 1999-08-26
AR017723A1 (es) 2001-09-12
PE20000266A1 (es) 2000-04-07
GT199900015A (es) 2000-07-26
EA199900124A3 (ru) 1999-12-29

Similar Documents

Publication Publication Date Title
TNSN99024A1 (fr) Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
MA27305A1 (fr) Derives de 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene et leur utilisation en tant qu'inhibiteurs de renine dans le traitement de l'hypertension, de maladies cardiovasculaires ou renales
TNSN98154A1 (fr) Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant
WO2002076979A8 (fr) Derives de 1,2,3,4-tetrahydro-isoquinoline en tant qu'antagonistes du recepteur de l'urotensine ii
WO2006070325A3 (fr) Derives de 2,3,4,9-tetrahydro-1h-carbazole utilises en tant qu'antagonistes des recepteurs de crth2
TNSN99110A1 (fr) Inhibiteurs non peptidiques de l'adhesion cellulaire sous la dependance de vla-4, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98019A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97048A1 (fr) Pyridines 2 - aryl - substituees.
WO2002042462A3 (fr) Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
WO2003017936A2 (fr) Utilisation d'inhibiteurs de la dppiv utilises comme agents diuretiques et anti-hypertenseurs
MA30342B1 (fr) Nouvelles compositions pour des troubles capillaires et procede de preparation de celles-ci
EP2289521A3 (fr) Compositions et procédé d'utilisation pour le ciblage de la destruction vasculaire
TNSN97114A1 (fr) Granule pour la preparation des compositions a desintegration et dissolution rapides comprenant une teneur elevee d'un principe actif
WO2002019969A3 (fr) Acide (5-(2-hydroxy-4-chlorobenzoyl) aminovalerique et ses sels, compositions contenant l'acide et ses sels pour acheminer des agents actifs
MA26741A1 (fr) Suspensions de ziprasidone nouvelles et procede pour leur preparation.
CA2326339A1 (fr) Utilisation de dexmedetomidine pour la sedation dans une unite de soins intensifs
TNSN98157A1 (fr) 2-aminopyridines alkoxy-substituees nouvelles, compositions pharmaceutiques les contenant et procede pour leur preparation
TNSN99002A1 (fr) Composes nouveaux inhibiteurs de mmp, procede pour leur preparation et compositions pharmaceutiques les contenant
RU2001118854A (ru) Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний
WO1999045909A3 (fr) Inhibition de l'angiogenese
CA2461625A1 (fr) Irbesartan entrant dans la preparation des produits medicaux utiles pour prevenir ou traiter l'hypertension arterielle pulmonaire
AP2001002119A0 (en) Sertraline oral concentrate.
TNSN98089A1 (fr) Composes d'ammonium quaternaire nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.